Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
Effective highly active antiretroviral therapy (HAART) has increased survival in patients infected with the human immunodeficiency virus (HIV). However, HAART is not without toxicities. Cutaneous adverse reactions from antiretroviral agents have become increasingly important to recognize as the population of patients surviving with HIV infection grows. Dermatologists play an important role in managing these cutaneous effects of HAART therapy in HIV patients. This article reviews cutaneous adverse effects from nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and fusion inhibitors, as well as separately addresses lipodystrophy, and immune reconstitution.
Kong
Heidi H
HH
Division of Dermatology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Myers
Sarah A
SA
D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000209:etiology; D006801:Humans; D012871:Skin Diseases / Q000139:chemically induced* / Q000276:immunology